Medical treatment of pulmonary arterial hypertension

Seminars in Respiratory and Critical Care Medicine

Volumn 30, Issue 4, 2009, Pages 484-492

  Adamali, Huzaifa ^a   Gaine, Sean P ^a   Rubin, Lewis J ^b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Combination therapy; Medical treatment; Pulmonary arterial hypertension

Indexed keywords

ADENOSINE; AMBRISENTAN; BERAPROST; BOSENTAN; CYCLOSPORIN; DIGOXIN; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ILOPROST; PLACEBO; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST; WARFARIN;

ARTHRALGIA; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DRUG HALF LIFE; DRUG MECHANISM; FLUSHING; HEADACHE; HEART RIGHT VENTRICLE FAILURE; HUMAN; JAW DISEASE; JAW PAIN; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; LUNG CIRCULATION; LUNG VASCULAR RESISTANCE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; TREATMENT RESPONSE;

ALGORITHMS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; EXERCISE TEST; HUMANS; HYPERTENSION, PULMONARY; PULMONARY ARTERY; SIGNAL TRANSDUCTION;

EID: 68049106393     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0029-1233317     Document Type: Review

References (80)

1. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-1928 (Pubitemid 46981654)
2. Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-2278
3. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43 (12, Suppl S):5S-12S
4. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006;114:1482-1489 (Pubitemid 44527003)
5. Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 1998;31:1650-1657
6. Parambil JG, McGoon MD. Pregnancy and pulmonary hypertension. In: Oakley C, Warnes CA, eds. Heart Disease in Pregnancy. Malden, MA: Blackwell; 2007:59-78
7. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000;160:191-196 (Pubitemid 30054338)
8. Kenyon KW, Nappi JM. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother 2003;37:1055-1062 (Pubitemid 36875240)
9. Warnes CA. Pregnancy and pulmonary hypertension. Int J Cardiol 2004;97(Suppl 1):11-13
10. Tarver JH, Rosas I, Diette GB, et al. Chronic ambulatory dopamine infusion therapy for refractory right heart failure due to pulmonary hypertension [abstract]. ARRCM 2000; 161:A459
11. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-587 (Pubitemid 14020655)
12. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 2006;130:545-552 (Pubitemid 44267025)
13. Kawut SM, Horn EM, Berekashvili KK, et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005;95:199-203 (Pubitemid 40092084)
14. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998;114:787-792 (Pubitemid 28433741)
15. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987;76:135-141 (Pubitemid 17093201)
16. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903 (Pubitemid 34984638)
17. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-3111 (Pubitemid 40847788)
18. Barst RJ, Rubin LJ, Long WA, et al; The Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-302
19. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000;132:425-434
20. Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995;48:890-896
21. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990;112:485-491 (Pubitemid 20100285)
22. McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999;130:740-743 (Pubitemid 29211512)
23. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99:1858-1865 (Pubitemid 29181415)
24. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30:641-648 (Pubitemid 29409407)
25. Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;15:1433-1439 (Pubitemid 36609730)
26. Cabrol S, Souza R, Jais X, et al. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2007;26:357-362 (Pubitemid 46522504)
27. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1184-1187 (Pubitemid 29500558)
28. McLaughlin VV, Gaine SP, Barst RJ, et al; Treprostinil Study Group. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003;41:293-299
29. Vachiéry JL, Hill N, Zwicke D, Barst R, Blackburn S, Naeije R. Transitioning from I.V. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002;121:1561-1565 (Pubitemid 34499671)
30. Tapson VF, McLaughlin VV, Gomberg-Maitland M, et al. Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension. J Vasc Access 2006;7:112-117 (Pubitemid 44613842)
31. Simonneau G, Barst RJ, Galie N, et al; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-804 (Pubitemid 34229650)
32. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006;28:1195-1203 (Pubitemid 44883856)
33. Olschewski H, Simonneau G, Galiè N, et al; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-329
34. Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 2005;26:1895-1902 (Pubitemid 41253303)
35. Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998;80:151-155 (Pubitemid 28389476)
36. Galiè N, Humbert M, Vachiéry JL, et al; Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-1502
37. Barst RJ, McGoon M, McLaughlin V, et al; Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-2125
38. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-1739 (Pubitemid 23170122)
39. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903 (Pubitemid 34984638)
40. Dupuis J. Endothelin-receptor antagonists in pulmonary hypertension. Lancet 2001;358:1113-1114
41. Dupuis J, Jasmin JF, Prié S, Cernacek P. Importance of local production of endothelin-1 and of the ET(B) receptor in the regulation of pulmonary vascular tone. Pulm Pharmacol Ther 2000;13:135-140 (Pubitemid 30834959)
42. Kirchengast M, Luz M. Endothelin receptor antagonists: clinical realities and future directions. J Cardiovasc Pharmacol 2005;45:182-191 (Pubitemid 40170682)
43. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-1123 (Pubitemid 32971843)
44. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-249 (Pubitemid 40246523)
45. Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006;27:589-595
46. Galié N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-535 (Pubitemid 41040298)
47. Galiè N, Olschewski H, Oudiz RJ, et al; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double- Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-3019
48. Oudiz R, Badesch D, Rubin L. ARIES-E: Long-term safety and efficacy of ambrisentan in pulmonary arterial hypertension [abstract]. Chest 2007;132:474a
49. Barst RJ, Langleben D, Badesch D, et al; STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-2056
50. Barst RJ. Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2007;8:95-109 (Pubitemid 46070832)
51. Barst RJ, Langleben D, Frost A, et al; STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-447
52. Barst RJ, Langleben D, Badesch D, et al; STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-2056
53. Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 2007;26:63-69 (Pubitemid 46096748)
54. Langleben D, Hirsch AM, Shalit E, Lesenko L, Barst RJ. Sustained symptomatic, functional, and hemodynamic bene- fit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2004;126:1377-1381 (Pubitemid 39391276)
55. Galiè N, Ghofrani HA, Torbicki A, et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-2157
56. Pepke-Zaba J, Gilbert C, Collings L, Brown MC. Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest 2008;133:183-189
57. Galiè N, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-2903
58. SimonneauG, Rubin LJ, Galiè N, et al; PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149: 521-530
59. Wilkens H, Guth A, König J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-1222 (Pubitemid 32848108)
60. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42:158-164 (Pubitemid 36760778)
61. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515-522 (Pubitemid 34252285)
62. United Therapeutics. TRIUMPH-1 trial of Viveta in pulmonary arterial hypertension meets primary endpoint. November 1, 2007. Available at: http://ir.unither.com/releasedetail.cfm?ReleaseID=272478
63. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-1263 (Pubitemid 44924827)
64. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691-694 (Pubitemid 46331988)
65. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-359 (Pubitemid 39232254)
66. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004;24:1007-1010 (Pubitemid 39642293)
67. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007;29:469-475 (Pubitemid 46372092)
68. Doyle RL, McCrory D, Channick RN, Simonneau G, Conte J; American College of Chest Physicians. Surgical treatments/ interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(1, Suppl):63S-71S
69. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006;25:745-755
70. American Academy of Hospice and Palliative Medicine; Center to Advance Palliative Care; Hospice and Palliative Nurses Association; Last Acts Partnership; National Hospice and Palliative Care Organization. National Consensus Project for Quality Palliative Care: Clinical Practice Guidelines for quality palliative care, executive summary. J Palliat Med 2004;7:611-627
71. Hoeper MM, Galié N, Murali S, et al. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165:341-344 (Pubitemid 34118506)
72. McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006;15:103-115 (Pubitemid 43097591)
73. Nagaya N, Nishikimi T, Goto Y, et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 1998;135:21-28 (Pubitemid 28073054)
74. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004;43:764-770 (Pubitemid 38296473)
75. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-870 (Pubitemid 30671502)
76. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum Nterminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006;129:1313-1321
77. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;39:1214-1219
78. Yeo TC, Dujardin KS, Tei C, Mahoney DW,McGoon MD, Seward JB. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998;81:1157-1161 (Pubitemid 28232689)
79. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006;174:1034-1041
80. Frantz RP, Benza RL, Kjellström B, et al. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2008;27:780-788